about
Present Advances and Future Perspectives of Molecular Targeted Therapy for OsteosarcomaPemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study.Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients.Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancerPemetrexed versus vinorelbine treatment of advanced non-squamous non-small cell lung cancer in elderly patientsEfficacies and adverse reactions of modified vitamin supplement programs before pemetrexed chemotherapy as a second-line treatment against epidermal growth factor receptor (EGFR) mutant wild-type lung adenocarcinoma.Concentration-dependent processivity of multiple glutamate ligations catalyzed by folylpoly-gamma-glutamate synthetase.Single agents with designed combination chemotherapy potential: synthesis and evaluation of substituted pyrimido[4,5-b]indoles as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents.Pemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: a limited access phase II trial of the gynecologic oncology group.Folylpolyglutamate synthetase gene transcription is regulated by a multiprotein complex that binds the TEL-AML1 fusion in acute lymphoblastic leukemia.Pemetrexed disodium in ovarian cancer treatment.Pemetrexed induced thymidylate synthase inhibition in non-small cell lung cancer patients: a pilot study with 3'-deoxy-3'-[¹⁸F]fluorothymidine positron emission tomography.Safety and efficacy of pemetrexed in maintenance therapy of non-small cell lung cancer.Increased risk of severe infections in non-small-cell lung cancer patients treated with pemetrexed: a meta-analysis of randomized controlled trials.Tailoring treatment of nonsmall cell lung cancer by tissue type: role of pemetrexed.Adaptation of a chemosensitivity assay to accurately assess pemetrexed in ex vivo cultures of lung cancerThymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma.The purinosome, a multi-protein complex involved in the de novo biosynthesis of purines in humans.The ERK-ZEB1 pathway mediates epithelial-mesenchymal transition in pemetrexed resistant lung cancer cells with suppression by vinca alkaloids.The role of maintenance pemetrexed in the treatment of non-small-cell lung cancer.Current therapeutic strategies and novel approaches in osteosarcoma.Metformin synergistic pemetrexed suppresses non-small-cell lung cancer cell proliferation and invasion in vitro.Safety profiles of first-line therapies for metastatic non-squamous non-small-cell lung cancer.Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer.Renal failure during chemotherapy: renal biopsy for assessing subacute nephrotoxicity of pemetrexed.The monomeric state of the proton-coupled folate transporter represents the functional unit in the plasma membrane.Comparison of pemetrexed and docetaxel as salvage chemotherapy for the treatment for nonsmall-cell lung cancer after the failure of epidermal growth factor receptor-tyrosine kinase inhibitors.Chemotherapy treatment in malignant pleural mesothelioma: a difficult history.Lansoprazole Exacerbates Pemetrexed-Mediated Hematologic Toxicity by Competitive Inhibition of Renal Basolateral Human Organic Anion Transporter 3.[Pemetrexed combined with cisplatin or carboplatin regimen in the treatment of advanced recurrent or metastasis non-small cell lung cancer: analysis of 63 cases].The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review.Chemotherapy with or without pemetrexed as second-line regimens for advanced non-small-cell lung cancer patients who have progressed after first-line EGFR TKIs: a systematic review and meta-analysis.
P2860
Q26750631-7B294802-DC74-4105-B68E-3FCDD344CCB9Q33383287-C35E1FA7-F09A-4C38-91A5-19EE4D0C423AQ33389316-98DE1D32-2C1F-4056-8D94-27D19287B92FQ33400687-793CAC7C-6D94-4F06-A5D0-48628643BAD3Q33414072-5C617965-25F6-462F-91ED-373C1DC15E01Q33427414-A05EACF8-60F9-4E77-8A76-50FBDA704260Q33586350-CEE86D0B-9336-4561-8508-F05CB26E2837Q33675186-84CC5A7D-36B2-4303-9483-6139E77E0DC2Q34091240-222965E6-53CC-4824-820D-AE4F17388B43Q34161064-B7CD5C59-C2F3-4E29-BC04-27C5FE215F13Q34253505-F1FF3CE1-D936-47DF-B761-A1C79BC59B79Q34744444-902AE57F-C693-4165-9B58-FCD00C0F57D3Q35789647-B400A32F-F0B9-4B9B-92E8-3156C3C77A03Q36122109-27DF75F3-73A9-4933-BD81-46923BBEF791Q36441443-22AF6CB0-9237-42A9-8872-B911A72FB0FEQ36591925-84488E54-EDA0-4064-B1C4-51DC2EE16EE1Q36696282-2B745E38-E9A4-417A-A8B1-3150BC8C5BB9Q37424854-1D38B9E3-B84B-4CB9-BCFE-1DEB667D99E5Q37590740-7DD9967E-38C0-4BE9-B62D-BA7E5D3014DAQ37645190-176BC0AA-9BB8-4E31-BCAA-7CC4796618FAQ38161735-12201189-7840-4900-B943-A5FAC382A5FDQ38674016-DBB56762-DA41-492E-BFD4-24F851A9AD8AQ38786021-ACD427C1-9E7B-4E3E-9499-C6D2374E5A09Q38983310-B805FBB0-6C04-44E1-8960-BBC37A4A210DQ47120870-A865E5D0-757F-4E0F-992E-5A6070115FEAQ48626485-FBE786F7-CA01-4E90-A41B-1EAFE629883DQ50736135-EA73E852-C02D-4849-A55E-E8F871AE5BB5Q52672893-8A420C74-EA6C-487B-99B6-C87AA80AE411Q53052634-87976FBE-1CF0-4B22-8DB7-2E4036AF16FAQ55429561-3F2B7908-F35F-4AEE-8786-3EBF1AD6758CQ55432585-40609923-A1D6-4F2E-B7E9-009A06C279DEQ55484524-FADFFAE8-D265-4C30-A70A-CA3D13AD3AFD
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Pemetrexed: a multitargeted antifolate.
@ast
Pemetrexed: a multitargeted antifolate.
@en
type
label
Pemetrexed: a multitargeted antifolate.
@ast
Pemetrexed: a multitargeted antifolate.
@en
prefLabel
Pemetrexed: a multitargeted antifolate.
@ast
Pemetrexed: a multitargeted antifolate.
@en
P1476
Pemetrexed: a multitargeted antifolate.
@en
P2093
Celeste Lindley
Kristan D Rollins
P304
P356
10.1016/J.CLINTHERA.2005.09.010
P577
2005-09-01T00:00:00Z